🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Xinqiao Hospital of Chongqing clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Xinqiao Hospital of Chongqing as lead sponsor. Synced 27 Sep 2026
14Current trials
11Recruiting now
4Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Xinqiao Hospital of Chongqing is the lead sponsor of 14 current clinical trials in our China register. 11 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Benmelstobart, Edaravone dexborneol sublingual and Tirofiban. The most-studied condition is Acute Ischemic Stroke.

ClinicalTrials.gov trials by status

  • Recruiting1179%
  • Not yet open321%

Trials by phase

  • Phase 2429%
  • Not applicable214%
  • Phase 3214%
  • Observational214%
  • Phase 4214%
  • Phase EARLY_PHASE117%
  • Phase 1/217%
01

Clinical trials sponsored by Xinqiao Hospital of Chongqing

14 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
NCT05754203 · ClinicalTrials.gov ↗ · Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy
Not applicable Recruiting 2023-08 China
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
NCT05147844 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma
Phase 2 Recruiting 2022-03 China
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
NCT06953843 · ClinicalTrials.gov ↗ · NSCLC Stage IV Without EGFR/ALK Mutation
Phase 2 Recruiting 2025-07 China
An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
NCT05486650 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
Observational Recruiting 2022-08 China
Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window
NCT06987305 · ClinicalTrials.gov ↗ · Stroke, Acute Ischemic
Phase 3 Recruiting 2025-10 China
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
NCT06279351 · ClinicalTrials.gov ↗ · Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Phase 2 Recruiting 2024-08 China
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
NCT05862259 · ClinicalTrials.gov ↗ · Malignant Tumor, Immunotherapy, Artificial Intelligence
Observational Recruiting 2023-08 China
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
NCT07349849 · ClinicalTrials.gov ↗ · B-cell Malignancies
Phase EARLY_PHASE1 Recruiting 2025-12 China
A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)
NCT05230914 · ClinicalTrials.gov ↗ · Stroke, Ischemic, Stroke, Acute
Not applicable Recruiting 2024-12 China
Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis
NCT05455034 · ClinicalTrials.gov ↗ · Pneumonitis
Phase 1/2 Recruiting 2023-08 China
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
NCT06947694 · ClinicalTrials.gov ↗ · NSCLC Stage IV Without EGFR/ALK Mutation
Phase 2 Recruiting 2025-07 China
Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
NCT07347626 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Phase 3 Not yet open 2026-03 China
Tirofiban Combined With Aspirin in Moderate Ischemic Stroke
NCT07760922 · ClinicalTrials.gov ↗ · Ischemic Stroke, Acute
Drug: Tirofiban
Phase 4 Not yet open 2026-10 China
Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS)
NCT07682922 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Phase 4 Not yet open 2026-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Xinqiao Hospital of Chongqing trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Xinqiao Hospital of Chongqing trials

17 conditions
Acute Ischemic Stroke2NSCLC Stage IV Without EGFR/ALK Mutation2Lung Cancer1Immune Checkpoint Inhibitor1Radiotherapy1Nasopharyngeal Carcinoma1Non Small Cell Lung Cancer1Ischemic Stroke, Acute1Stroke, Acute Ischemic1Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer1Malignant Tumor1Immunotherapy1Artificial Intelligence1B-cell Malignancies1Stroke, Ischemic1Stroke, Acute1Pneumonitis1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1411

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Acute Ischemic Stroke

SponsorTrials
Capital Medical University14
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University7
Xuanwu Hospital, Beijing6
Universitätsklinikum Hamburg-Eppendorf4
Nanfang Hospital, Southern Medical University4
Beijing Anzhen Hospital4
Yi Yang4
The First Affiliated Hospital of University of Science and Technology of China4
The First Affiliated Hospital of Zhengzhou University3
Xiang Luo3

Sponsors with the most current trials registered for this condition.

06

Questions about Xinqiao Hospital of Chongqing trials

How many clinical trials does Xinqiao Hospital of Chongqing sponsor?

Xinqiao Hospital of Chongqing is the lead sponsor of 14 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Xinqiao Hospital of Chongqing trials recruiting?

Yes. 11 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Xinqiao Hospital of Chongqing testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Benmelstobart (1), Edaravone dexborneol sublingual (1), Tirofiban (1) and Toripalimab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.